Sartorius
Stedim India on expansion mode
Sartorius Stedim Biotech
focuses on single-use technologies and value-added services to meet the
rapidly changing technology requirements of the industry it serves.
The Sartorius Group is an internationally
renowned Germany-based laboratory and process technology provider
covering biotechnology and mechatronics. Sartorius Stedim Biotech is
one of the leading providers of cutting-edge equipments and services
for the development, quality assurance and production processes of the
biopharmaceutical industry. Its integrated solutions covering
fermentation, filtration, purification, fluid management and lab
technologies are supporting the biopharmaceutical industry around the
world to develop and produce drugs safely, timely and economically. For
next generation processes, Sartorius Stedim Biotech focuses on
single-use technologies and value-added services to meet the rapidly
changing technology requirements of the industry it serves. Key
Sartorius customers are from the pharmaceutical, chemical and food and
beverage industries and from numerous research and educational
institutes of the public sector. The company employs
approximately 2,300 people globally.
Through its presence in India, Sartorius brings all the expertise of
Sartorius group to its Indian customers apart from adding value through
quality manufacturing of engineered systems both in biotechnology and
mechatronics. The Indian manufacturing operations cover all aspects of
Sartorius business like flat filters, standard and customized
engineered systems, R&D. It exports its products and components
to group companies in Germany and other Asian countries.
Sartorius Stedim India has invested €5 million in a
spanking new integrated facility in Bangalore that will house
state-of-the-art manufacturing. It has already started operations in
its new R&D facility which covers cell culture, microbiology,
process development studies and filter validation studies.
Sartorius is making a substantial expansion of its technology portfolio
in the area of single-use bioreactors. The company is bringing out two
prototypes of innovative single-use bioreactors that operate based on
novel mixing technologies. These cell culture systems were developed in
cooperation with the German company Bayer Technology Services
(BTS) and the Swiss cell culture specialist ExcellGene. The new
bioreactors have been specially designed for the manufacture of
monoclonal antibodies, recombinant proteins and vaccines.
In 2010, the company plans to extend its technology portfolio by two
further systems: a rotationally oscillating bioreactor and an orbital
shake bioreactor. Each of these four agitation technologies offers
users specific advantages contingent upon the cells to be produced, the
scale-up level of the cell cultures and additional process
parameters.